Erectile Dysfunction Following Radical Prostatectomy Clinical Trial
Official title:
Effect of Early Shockwave Therapy Protocol for Preservation and Restoration of Erectile Function After Nerve-sparing Radical Prostatectomy
NCT number | NCT03905057 |
Other study ID # | EspPRP-ED_001 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | March 26, 2018 |
Est. completion date | June 2021 |
This pilot study aims to explore the feasibility, safety and effectiveness of two different extracorporeal shock wave therapy (ESWT) protocols for patients receiving nerve-sparing radical prostatectomy (RP).
Status | Recruiting |
Enrollment | 94 |
Est. completion date | June 2021 |
Est. primary completion date | June 2021 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 50 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Men scheduled for robotic bilateral nerve-sparing radical prostatectomy - Diagnosed with low/intermediate-risk prostate cancer: - PSA < 20 ng/ml - Gleason score < 8 - PCa stage =< T2b - Baseline IIEF-ED 22-30 without erectogenic aids - No urinary incontinence (no usage of urinary pads) - Sexually active, in a stable heterosexual relationship - Able to understand and complete patient questionnaires - Consent to participate Exclusion Criteria: - Anatomical abnormalities in the genitalia or pelvic region - Post-RP complications that could impact safety or effectiveness of ESWT (eg. hematoma, fistula, unresolved anastomotic leak) - Incomplete tumor removal (positive surgical margin) - Tumor upstaging beyond T2b - Nerve sparing score < 4 - Previous or scheduled treatment with pelvic radiotherapy and/or androgen deprivation therapy - Untreated hypogonadism (serum total testosterone < 300 mg/dL) - Anti-coagulant medication, or any blood coagulation disorders (INR > 3) - Any other condition that would prevent the patient from completing the study, as judged by the principle investigator |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitari de Bellvitge | L'Hospitalet de Llobregat | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Dornier MedTech Systems | Hospital Universitari de Bellvitge |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The difference in average Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF) between the groups at 28-week follow up | EF domain of the IIEF questionnaire will be completed. IIEF-EF consists of items 1,2,3,4,5,15 of the IIEF questionnaire.According to the score of the iIEF-EF there are five categories of erectile function: 1-10 (Severe Erectile Dysfunction), 11-16(Moderate dysfunction), 17-21(Mild to moderate dysfunction), 22-25(Mild dysfunction), 26-30 (No dysfunction) | 28-week follow up visit | |
Primary | The difference in average Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF) between the groups at 24-month follow up | EF domain of the IIEF questionnaire will be completed. IIEF-EF consists of items 1,2,3,4,5,15 of the IIEF questionnaire.According to the score of the iIEF-EF there are five categories of erectile function: 1-10 (Severe Erectile Dysfunction), 11-16(Moderate dysfunction), 17-21(Mild to moderate dysfunction), 22-25(Mild dysfunction), 26-30 (No dysfunction) | 24-month follow up visit | |
Secondary | Proportion of patients achieving Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF) of 22-30 in each group | The proportion of patients achieving Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF) of 22-30 (indicating mild to no erectile dysfunction) in each group. EF domain of the IIEF questionnaire will be completed. IIEF-EF consists of items 1,2,3,4,5,15 of the IIEF questionnaire.According to the score of the iIEF-EF there are five categories of erectile function: 1-10 (Severe Erectile Dysfunction), 11-16(Moderate dysfunction), 17-21(Mild to moderate dysfunction), 22-25(Mild dysfunction), 26-30 (No dysfunction). | baseline, 12-weeks post-RP, 24-weeks post-RP, 28-weeks post-RP, 52-weeks post-RP, 18-months post-RP and 24-months post-RP | |
Secondary | Change in each domain of the full International Index of Erectile Function (IIEF) score | Change in each domain of the full International Index of Erectile Function (IIEF) score from baseline and from each follow-up. EF domain of the IIEF questionnaire will be completed. IIEF-EF consists of items 1,2,3,4,5,15 of the IIEF questionnaire.According to the score of the iIEF-EF there are five categories of erectile function: 1-10 (Severe Erectile Dysfunction), 11-16(Moderate dysfunction), 17-21(Mild to moderate dysfunction), 22-25(Mild dysfunction), 26-30 (No dysfunction) | baseline, 12-weeks post-RP, 24-weeks post-RP, 28-weeks post-RP, 52-weeks post-RP, 18-months post-RP and 24-months post-RP | |
Secondary | Change in Erection Hardness Score | The Erection Hardness Score (EHS) is a single-item Likert scale to assess erectile dysfunction. Male patients have to answer the question "How would you rate the hardness of your erection?". They answer by selecting from the following options: 0 = Penis does not enlarge; 1 = Penis is large, but not hard; 2 = Penis is hard, but not hard enough for penetration; 3 = Penis is hard enough for penetration, but not completely hard; 4 = Penis is completely hard and fully rigid. | baseline, 12-weeks post-RP, 24-weeks post-RP, 28-weeks post-RP, in-office ICI visits, 52-weeks post-RP, 18-months post-RP and 24-months post-RP | |
Secondary | Change in Global Assessment Questionnaire (GAQ) score | The Global Assessment Questionnaire (GAQ) is a tool to evaluate the efficacy of the treatment. Patients will be asked and provide scores (on a scale of 1 to 5) for treatment related, with a score of 1 being least favourable and 5 being most favourable. | 12-weeks post-RP, 24-weeks post-RP, 28-weeks post-RP, 52-weeks post-RP, 18-months post-RP and 24-months post-RP | |
Secondary | Change in stretched flaccid penile length | The flaccid penis of each patient will be stretched and measured from the base of the penis to the tip of the glans. | baseline, 12-weeks post-RP, 24-weeks post-RP, 52-weeks post-RP, 18-months post-RP and 24-months post-RP | |
Secondary | Change in degree of incontinence | Incontinence will be determined by the number of pads used per day and the time to achieve 0-1 pad will be compared between the groups. | First treatment session, 12-weeks post-RP, 24-weeks post-RP, 52-weeks post-RP, 18-months post-RP and 24-months post-RP | |
Secondary | Oncologic status | The oncologic status of each patient will be evaluated determined by the serum prostate specific antigen (PSA) levels. | 12-weeks post-RP, 24-weeks post-RP, 52-weeks post-RP, 18-months post-RP and 24-months post-RP | |
Secondary | Time to recovery of penetration erection hardness without erectogenic aids | Penetration erection hardness is having an EHS score of 3-4. The Erection Hardness Score (EHS) is a single-item Likert scale to assess erectile dysfunction. Male patients have to answer the question "How would you rate the hardness of your erection?". They answer by selecting from the following options: 0 = Penis does not enlarge; 1 = Penis is large, but not hard; 2 = Penis is hard, but not hard enough for penetration; 3 = Penis is hard enough for penetration, but not completely hard; 4 = Penis is completely hard and fully rigid. | baseline, 12-weeks post-RP, 24-weeks post-RP, 28-weeks post-RP, in-office ICI visits, 52-weeks post-RP, 18-months post-RP and 24-months post-RP | |
Secondary | Tolerability to and reliance on intracavernosal injections for satisfactory erections: Visual Analog Scale for Pain | Patients who are unsatisfied with their erectile function at the 28 week visit, will be offered intracavernosal injections (10mg PGE1, 2x/week) for the remaining duration of the study. During each in-office ICI, patients will report pain tolerability (Visual Analog Scale for Pain), and maximum EHS achieved. Patients will be allowed to stop ICI if they report satisfactory erections without any erectogenic aids for 2 weeks. Patients will be allowed to resume ICI if erectile function decreases, and they report unsatisfactory erections with erectogenic aids for 2 weeks. Dates of stopping and/or resuming ICI will be recorded. At the 52 weeks, 18 and 24 months post-RP follow-up sessions, All patients will self-administer ICI of 10mg PGE1 during the visit, and report pain tolerability (Visual Analog Scale for Pain), and maximum EHS achieved. | ICI visits, 52-weeks post-RP, 18-months post-RP and 24-months post-RP |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05735223 -
A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic Laparoscopic Prostatectomy on the Stretched Flaccid Penile Length and Continence
|
N/A | |
Recruiting |
NCT05868668 -
Efficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain
|
N/A | |
Completed |
NCT03241758 -
Vascular Changes Of Patients Undergoing Laparoscopic Radical Prostatectomy
|
N/A | |
Recruiting |
NCT05558007 -
Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
|
Phase 2 | |
Completed |
NCT05332340 -
Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered
|
Phase 1 | |
Completed |
NCT04491773 -
Study of Retinal and Choriocapillary Vascular Changes in Patients Undergoing Tadalafil 20mg for More Than 6 Months
|
||
Recruiting |
NCT05650866 -
Safety and Tolerability of a Novel Implantable Device for the Treatment of Erectile Dysfunction
|
N/A | |
Not yet recruiting |
NCT06126874 -
Additional Effects of Aerobic and Resistance Exercises to Pelvic Floor Muscle Training After Radical Prostatectomy
|
N/A | |
Completed |
NCT05772598 -
Validating the 'Sexual Minorities and Prostate Cancer Scale' to Gold Standard Questionnaires
|
||
Recruiting |
NCT05244486 -
Efficacy of RestoreX Penile Traction Therapy In Preserving Erectile Function Post-Prostatectomy
|
N/A | |
Not yet recruiting |
NCT06458855 -
Nerve Grafting Technique to Restore Erectile Function Post Radical Prostatectomy
|
N/A | |
Completed |
NCT00335634 -
Sexual Dysfunction and Adaptation in Couples Affected by Prostate Cancer Surgery
|
N/A | |
Recruiting |
NCT03862599 -
Low Intensity Shock-wave Therapy (Li-ESWT) in Penile Rehabilitation After Radical Prostatectomy
|
N/A | |
Active, not recruiting |
NCT04434352 -
Low Intensity Shockwave Therapy for Erectile Dysfunction
|
N/A | |
Completed |
NCT04164355 -
Study of Retinal and Choriocapillary Vascular Changes in Patients Undergoing Tadalafil 20mg
|
||
Not yet recruiting |
NCT05960149 -
Use of Indocyanine Green in Robotic Prostate Surgeries
|
Phase 4 | |
Terminated |
NCT01996852 -
Improving Erectile Function and Quality of Life After Prostate Cancer Treatment
|
N/A | |
Recruiting |
NCT06076850 -
Low-Intensity Extracorporeal Shockwave Therapy for Penile Rehabilitation in Post-Radical Prostatectomy Patients
|
N/A | |
Terminated |
NCT01770340 -
Nerve Grafting With an Allograft During Radical Prostatectomy - Extended Follow-up in a Prospective Randomized Trial
|
Phase 4 | |
Not yet recruiting |
NCT05578157 -
MENDiP: Measurements of Overnight Penile Temperature to Evaluate Nocturnal Erection Detection in Patients With Absence of Erectile Functioning After Robot-assisted Radical Prostatectomy
|